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Abstract 
Prostate cancer is the second common form of cancer in men. Detection of circulating Prostate Specific Antigen (PSA) tran-
scripts has effectively been used for early diagnosis of prostate cancer cells. This investigation employed a reverse tran-
scriptase polymerase chain reaction (RT-PCR) technique to distinguish the patients with either localized or metastatic pros-
tate cancer (CaP) vs. Benign Prostate Hyperplasia (BPH) and control subjects, as compared with clinical and pathological 
records. With reservation of ethical issues, blood samples were collected from 60 cases. Based on pathological and clinical 
findings, 25 patients (20 with localized cancer, 5 with metastatic), 22 with BPH, and 13 healthy (including 3 females) sub-
jects as negative controls, were selected from Shariati, Mehrad, Sina,, Khatam and Atie Hospitals in Tehran, Iran. RT-PCR 
for a 260 bp PSA transcript was then performed. Clinical and pathological records were used for the assessment and com-
parison of PSA RT-PCR results. None of the control subjects and BPH (with 7 exceptions) were found positive by RT-PCR 
(Relative specificity= 72.7%). In patients with prostate cancer, 21 out of 25 were found PSA positive (Relative sensitivity= 
83.4%) and the remaining 3 have been shown to be PSA negative (Positive predictive value= 83.4%). All of 5 metastatic 
patients (100%) revealed PSA positive results. Our data reflects the clinical relevance and significance of RT-PCR results as 
assessed with clinical and pathological examinations. PSA RT-PCR might be used as a powerful means for diagnosis, even 
when either pathological or clinical findings are negative, and could be employed for further molecular epidemiology sur-
veys.  
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Introduction  
Prostate cancer is the second leading cause of 
cancer in men in the United States (1-3). It is 
the most common form of cancer in men (fol-
lowed closely by lung cancer) in the world, and 
more than 300,000 new cases are detected 
every year (4, 5). Evaluation of the serum pros-
tate specific antigen (PSA) levels has been con-
sidered as the early detection test of prostate 
cancer (6). Although PSA is effective at identi-
fying prostate cancer (CaP) in men, it is also 
elevated in men with benign prostate hyperpla-
sia (BPH) and other prostate disorders (5). 
Therefore to distinguish CaP from other non-
malignant diseases, specific molecular markers 
are needed (5). For this reason, detection of cir-
culation PSA transcripts has effectively been 
used for early diagnosis of malignant prostate 
cells (7-10). PSA is a 34-kDa serine protease, 
produced by the prostate epithelial cells be-
longing to the third member of human glandu-
lar kalikrein family hk1, hk2 and hk3 (PSA). 
Hk2 is strongly expressed in the prostate (11). 
They are all encoded by genes located on chro- 
mosome 19q13.3-13.4 (12). PSA is secreted into 
seminal fluid at concentrations of 0.5-3 mg/ml 
(i.e., about 1 million times those of plasma) 
(13). PSA dissolves the gel forming after ejacu- 
lation by digesting seminogelin -1 and -2 and 
fibronectin, causing release of the sperm, which 
is essential for sperm function (14). 
In the normal prostate, natural barriers (includ-
ing epithelial and basal cell layer and the base-
ment membrane) minimize PSA leakage. In 
prostate carcinoma the basement membrane and 
the basal cell layer are disrupted (15). For this 
reason prostate epithelial cells loose organiza-
tion and may infiltrate the surrounding stroma. 
These changes contribute to the increased pas-
sage of PSA into the blood of prostate cancer 
patients (16). Many investigators have focused 
on the use of a very powerful and sensitive mo- 
lecular tool RT-PCR (reverse transcriptase po- 
lymerase chain reaction) to observe PSA tran-
script (17-20). This investigation employed an 
RT-PCR technique to distinguish the patients 
with either localized or metastatic prostate can-
cer CaP vs. BPH and control subject as com-
pared with clinical and pathological records.  
 
Materials and Methods 
Patients and Samples     All patients in this 
study, except control subjects, were selected 
according to clinical and pathological records 
either for adenocarcinoma of the prostate or 
BPH at the urology section, Shariati, Mehrad 
and Sina Hospitals, Tehran University of Medi-
cal Sciences, Iran.  
From 15 May 2002 to 5 January 2004, 60 pa-
tients, mean age 68.4 years (ranged 50-87), 
were included in this study. All patients except 
control subjects had been subjected to biopsy as 
a result of their abnormal digital rectal exam 
(DRE) and elevated serum PSA levels. 
Six ml peripheral blood sample, treated with 
sodium-citrate, from all patients were collected 
either immediately before radical prostatectomy 
at surgery room or before biopsy. A question-
naire was filled in for all patients according to 
International Prostate Symptom Score (IPSS) 
standard (21). Whole blood samples were di-
vided in two aliquots for further RNA extrac-
tions: one used freshly and, the other kept deep 
freezed for further repeats.  
Statistical analyses: All collected data on 
RT-PCR results were compared separately with 
either clinical findings or pathological records. 
Relative sensitivity, relative specificity, and 
relative positive predictive value (PPV) were 
calculated there on.  
Cell Lines     Two human prostate cancer cell 
lines, PC3 (22) and LNCaP (23), obtained from 
Pasteur Institute of Iran, were included in this 
study. These cells were used as positive con-
trols. 
RNA Extraction     The blood samples were 
received in 6 ml aliquots and kept in four dif-
ferent ways for further applications: 1-freezed 
whole blood, 2-freezed whole blood in equal 
volumes of guanidine isothiocyanate (GITC), 3- 
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freezed buffy coat in equal volume of GITC 
and 4-fresh buffy coat in equal volume of 
GITC, respectively. The fresh samples were 
immediately centrifuged at 10000 rpm for 15 
min. The buffy coat transferred to a new tube, 
washed one time by an equal volume of phos-
phate buffer saline (PBS). Total RNA extrac-
tion from the above samples, either fresh or 
freezed, was performed according to Chomzin-
sky method with slight modifications (24).      
In brief, cells were lyzed in GITC solution 
(Bohringer Mannheim-Germany),then extracted 
with phenol, chloroform, isopropanol, and pre- 
cipitated by absolute ethanol. The quality of the 
isolated RNAs was verified by control RT-PCR 
reactions using a house keeping gene, gamma 
actin. Extracted RNA was also evaluated by 
running an aliquot on a 1% agarose gel.  
Reverse transcription reaction (cDNA synthe-
sis)     For cDNA synthesis a First Strand 
cDNA Synthesis kit was used (Roche Inc., 
GMBH, Germany). According to kit instruc-
tions, an aliquot of Reaction Mix was prepared 
containing 4µl 5x buffer, 2µl dithiothreitol 
(DTT), 1µl deoxyribonucleotide mix (dNTP10 
mM), 1µl oligo deoxy thymidine (dt), 1µl ran-
dom hexamer, and 0.15µl RNase inhibitor 
added by 1.5µl moloneymurine leukemia virus 
reverse transcriptase enzyme (MMLV) and 
nearly one microgram total RNA. The volume 
was reached to 25µl by H2O. Using a pro-
grammable thermocycler, synthesis of cDNA 
was carried out for 55 min. at 38º C, followed 
by incubation at 95º C for 3min and equili-
brated at 20º C for 1 min. 
PCR (polymerase chain reaction)     The  prim-
ers for PSA gene were chosen as described ear-
lier (21). The sequence of PSA sense primer 
with 18 mer length was as follows: 5'-GCA 
CCC GGA GAG CTG TGT-3', and the se-
quence of PSA antisense primer with 21 mer 
length was as follows:  5'-GAT CAC GCT TTT 
GTT CCT GAT-3', (MWG Oligo Synthesis 
Company). In the PCR reaction, 5µl of pre-
pared cDNA was amplified in a 25µl aliquot 
containing 2.5µl (10X buffer+ MgCl2), 2µl 
MgCl2 (50mM), 1µl dNTP (10 mM), 2µl (20 
pM) of each sense and antisense primers and 
0.5µl. Thermus aquaticus (taq) enzyme (500U 
super taq DNA polymerase), and the rest 
ddH2O. After holding 3 min at 95º C (initial de- 
naturation), 40 cycles were repeated at 94º C/20 
sec (denaturation), 54º C/20 (annealing) and 72º 
C/ 30 (extension), respectively, followed by 10 
min at 72º C and terminated for 1 min at 20º C.  
 
Results 
We used four different ways in order to save 
RNA during extraction (Fig.1). The visualized 
28S and 18S ribosomal RNA bands were in-
dicative of RNA integrity. As Fig. 1 shows in 
line 4, a better quality of RNA was achieved 
when fresh buffy coat was used as the starting 
sample. Thus the 4th way of sample collection 
was applied for the further steps during the 
study. The PCR products, containing 260 bp 
PSA primers (25) and 1104 bp gamma actin 
primer were evaluated by 1% agarose gel elec-
trophoresis and visualized after staining by 
ethidium bromide (Fig.2). It was also evaluated 
by PAGE (Polyacrylamide- gel electrophoresis) 
and visualized after silver staining (Fig.3). As it 
is shown in these two figures, normally more 
bands are seen in the PAGE gel after silver 
staining, owing to the higher sensitivity of this 
method. However, a clear PSA band with iden-
tical electrophoresis characteristics is seen in 
the two gels. 
RT-PCR for PSA transcript was performed on 
samples from 25 patients with CaP, 22 patients 
with BPH, 10 healthy male and 3 healthy fe-
male subjects. Of the 25 prostate cancer pa-
tients, 20 had clinically localized and the rest 
had metastatic prostate cancer. 
RT-PCR showed no positive results for PSA in 
samples derived from normal individuals. The 
PSA transcript however, was detected in 31.8% 
BPH, 100% metastases and 80% localized 
prostate cancer patients, respectively. (Table1) 
When pathological data were considered as 
gold standard, the compared RT-PCR positivity 
was 27.3% for BPH, 100% for metastases, and 
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78.6% for localized patients, respectively 
(Table 2). 
In summary none of the control subjects and 
BPH (with 7 exceptions) were found positive 
by RT-PCR (Relative specificity= 72.7%). In 
patients with prostate cancer, 21 out of 25 were 
found PSA positive (Relative sensitivity= 
83.4%) and the remaining 3 have shown PSA 
negative (Positive predictive value= 83.4%). 
All of 5 metastatic patients (100%) revealed 
PSA positive results. 
 
 
 
Fig. 1: Extraction of RNA by gel electrophoresis by 
fresh & freezed blood 
 
 
 
 
Fig. 2: Optimization of LNcap cDNA in the human 
prostate cancer cell line 
 
 
 
 
 
Fig. 3: RT-PCR for PSA in patients as analyzed with silver staining method. line 1-2, 1114-bp molecular weight marker 
VIII (Life Technologies, Inc.). Line 3-7 localized cancer, line 8, 9 BPH; line 10-12 control subjects were analyzed. The 
PCR product is 260 bp for PSA. 
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Table 1: Correlation between PSA RT-PCR & clinical results 
  
PSA RT-PCR Total Positive Negative 
Classification of Patients No No % No % 
rostate cancer (Localized) 20 16 80 4 20 
Prostate cancer (Metastatic) 5 5 100 0 0 
Benign prostate hyperplasia (BPH) 22 7 31.81 15 68.18 
Control negative subjects (men) 10 0 0 10 100 
Control negative subjects (women) 3 0 0 3 100 
Total 60 28 46.66 32 53.33 
 
Table 2: Correlation between PSA RT-PCR & pathological results 
 
PSA RT-PCR Total Positive Negative 
Classification of Patients No No % No % 
Prostate cancer (Localized) 14 11 78.57 3 21.42 
Prostate cancer (Metastatic) 4 4 100 0 0 
Benign prostate hyperplasia (BPH) 11 3 27.27 8 72.72 
Control negative subjects (men) 10 0 0 10 100 
Control negative subjects (women) 3 0 0 3 100 
Total 42 18 42.85 24 57.14 
 
 
Discussion 
In the present study, we performed peripheral 
blood- based RT-PCR assay for PSA in Iranian 
prostate cancer versus BPH patients compared 
to healthy individuals as control. For each in-
cluded sample, the obtained RT-PCR result was 
then compared to the clinical examination re-
cord to evaluate their association with the 
pathological data. Collectively, our results 
showed that PSA RT-PCR was a more sensitive 
and specific method in screening prostate can-
cer patients that was in agreement with other 
studies (1, 2, 7). However, in 7 of 22 BPH 
cases, PCR was revealed positive. This result, 
which hinders PCR specificity, might be to 
some extent stemmed from the fact that patho-
logical examinations were made on only 3 of 
the 7 PCR positive BPH patients. Clinical ob-
servations are subjective and usually prone to 
error. Based on pathological data gathered from 
biopsies, our data demonstrate that the pre-
sented RT-PCR method allows detection of cir-
culating prostatic cells with PSA expression 
characteristics. Debate still exists on the valid-
ity and clinical significance of detecting circu-
lating prostate cancer cells using RT-PCR tech-
nology (26, 27). However, in line with some 
reported studies, our data shows more signifi-
cant correlation, than clinical criteria, between 
RT-PCR and Glisson Pathological Grading of 
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prostate cancer (2, 7, 9). In summary, none of 
the control subjects were found positive ac-
cording to RT-PCR relative specificity (72.7%). 
In clinically identified BPH patients, 7 of 22, 
revealed positive RT-PCR results. This positiv-
ity however, was lowered down to 3 of 11 cases 
when pathological data included as gold stan-
dard. In patients with prostate cancer, either 
metastatic or localized, 21 of 25 were found 
PSA positive (Clinically relative sensitivity, 
83.4%) and the remaining 4 have showed PSA 
negative (Positive predictive value (83.4%). All 
of 5 metastatic patients (100%) revealed PSA 
positive RT-PCR results. Collectively, these re-
sults advocate the promising applications of 
RT-PCR as a powerful gold-standard test for 
screening and monitoring patients suffering 
from prostate cancer. Our data reflects the clini-
cal relevance and significance of RT-PCR re-
sults as assessed with clinical and pathological 
examinations. PSA RT-PCR might be used as a 
powerful means for diagnosis, even when either 
pathological or clinical findings are negative, 
and could be employed for further molecular 
epidemiology surveys. 
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